Table 1.
Baseline characteristics of atorvastatin initiators and rosuvastatin initiators.
| Variables | Atorvastatin (n = 2605) | Rosuvastatin (n = 717) | Standardized difference | P value |
|---|---|---|---|---|
| Age (years, mean [SD]) | 62.17 (11.22) | 62.66 (10.59) | 0.045 | 0.30 |
| Men (no. [%]) | 1817 (69.75%) | 500 (69.74%) | <0.001 | 0.99 |
| BMI (mean [SD]) | 24.62 (3.33) | 24.76 (3.31) | 0.042 | 0.33 |
| Diagnosis (no. [%]) | ||||
| Ischemic stroke | 2341 (89.87%) | 641 (89.40%) | 0.015 | 0.72 |
| Transient ischemic attack | 264 (10.13%) | 76 (10.60%) | ||
| NIHSS total score | ||||
| Mean (SD) | 4.20 (4.20) | 4.23 (4.13) | 0.007 | 0.88 |
| ≤3 (no. [%]) | 1402 (53.82%) | 379 (52.86%) | 0.019 | 0.65 |
| Treatment (no. [%]) | ||||
| Intravenous thrombolysis | 538 (20.65%) | 138 (19.25%) | 0.035 | 0.41 |
| Endovascular therapy | 22 (0.84%) | 6 (0.84%) | <0.001 | 0.98 |
| Comorbidities (no. [%]) | ||||
| Lipid metabolism disorders | 902 (34.63%) | 216 (30.13%) | 0.096 | 0.024 |
| Pathoglycemia | 735 (28.21%) | 185 (25.80%) | 0.054 | 0.20 |
| Hypertension | 1840 (70.63%) | 505 (70.43%) | 0.004 | 0.92 |
| Coronary heart disease | 405 (15.55%) | 93 (12.97%) | 0.073 | 0.087 |
| Atrial fibrillation | 202 (7.75%) | 60 (8.37%) | 0.023 | 0.59 |
| Liver disease | 143 (5.49%) | 34 (4.74%) | 0.034 | 0.43 |
| Renal insufficiency | 25 (0.96%) | 5 (0.70%) | 0.029 | 0.87 |
| Personal lifestyle (no. [%]) | ||||
| Smoking | 1267 (48.64%) | 369 (51.46%) | 0.057 | 0.18 |
| Alcohol consumption | 1217 (46.72%) | 319 (44.49%) | 0.045 | 0.29 |
| Physical activity | 1567 (60.15%) | 422 (58.86%) | 0.026 | 0.53 |
| Disease history (no. [%]) | ||||
| Stroke | 385 (14.78%) | 97 (13.53%) | 0.036 | 0.40 |
| Transient ischemic attack | 74 (2.84%) | 14 (1.95%) | 0.058 | 0.19 |
| Lipid metabolism disorders | 129 (4.95%) | 45 (6.28%) | 0.058 | 0.16 |
| Diabetes | 503 (19.31%) | 129 (17.99%) | 0.034 | 0.43 |
| Hypertension | 1554 (59.65%) | 403 (56.21%) | 0.070 | 0.10 |
| Heart diseases | 347 (13.32%) | 95 (13.25%) | 0.002 | 0.96 |
| Infection within two weeks | 67 (2.57%) | 23 (3.21%) | 0.038 | 0.41 |
| Migraine | 36 (1.38%) | 13 (1.81%) | 0.034 | 0.61 |
| Medication history (no. [%]) | ||||
| Antiplatelet agents | 214 (8.21%) | 55 (7.67%) | 0.020 | 0.64 |
| Anticoagulant agents | 22 (0.84%) | 3 (0.42%) | 0.054 | 0.24 |
| Antidiabetic agents | 405 (15.55%) | 92 (12.83%) | 0.078 | 0.071 |
| Antihypertensive agents | 1096 (42.07%) | 290 (40.45%) | 0.033 | 0.43 |
| Laboratory data (mean [SD]) | ||||
| HDL-C (mmol/L) | 1.14 (0.30) | 1.13 (0.30) | 0.033 | 0.39 |
| LDL-C (mmol/L) | 2.60 (0.96) | 2.51 (0.97) | 0.093 | 0.12 |
| Triglycerides (mmol/L) | 1.59 (1.10) | 1.57 (0.85) | 0.020 | 0.62 |
| Alanine aminotransferase (U/L) | 21.40 (15.50) | 22.35 (17.37) | 0.058 | 0.17 |
| Aspartate aminotransferase (U/L) | 20.98 (9.95) | 21.41 (10.09) | 0.043 | 0.31 |
| eGFR (mL/min/1.73m2) | 95.83 (22.80) | 96.14 (24.61) | 0.013 | 0.75 |
| Uric acid (μmol/L) | 304.98 (90.11) | 309.23 (93.05) | 0.046 | 0.27 |
| Fasting glucose (mmol/L) | 6.50 (2.66) | 6.48 (2.81) | 0.007 | 0.87 |
| Calendar year of onset (no. [%]) | ||||
| 2015 | 554 (21.27%) | 133 (18.55%) | Reference | 0.013 |
| 2016 | 874 (33.55%) | 286 (39.89%) | 0.148 | |
| 2017 | 1154 (44.30%) | 290 (40.45%) | 0.021 | |
| 2018 | 23 (0.88%) | 8 (1.12%) | 0.079 | |
| Medical centers classified by the four economic regions of China (no. [%]) | ||||
| Eastern region | 1150 (44.15%) | 320 (44.63%) | Reference | 0.18 |
| Central region | 812 (31.17%) | 197 (27.48%) | 0.020 | |
| Western region | 381 (14.63%) | 117 (16.32%) | 0.024 | |
| Northeastern region | 262 (10.06%) | 83 (11.58%) | 0.045 | |
BMI, body mass index; eGFR, estimated Glomerular Filtration Rate; mRS, modified Rankin scale; NIHSS, National Institute of Health stroke scale; SD, standard deviation.